biostudies-literatureBaek MSSoonchunhyang UniversityKorea Disease Control and Prevention Agencye353https://www.ebi.ac.uk/biostudies/studies/S-EPMC10593602biostudies-literatureUnknown38(41)<h4>Background</h4>There is insufficient data on the benefits of empiric antibiotic combinations for hospital-acquired pneumonia (HAP). We aimed to investigate whether empiric anti-pseudomonal combination therapy with fluoroquinolones decreases mortality in patients with HAP.<h4>Methods</h4>This multicenter, retrospective cohort study included adult patients admitted to 16 tertiary and general hospitals in Korea between January 1 and December 31, 2019. Patients with risk factors for combination therapy were divided into anti-pseudomonal non-carbapenem β-lactam monotherapy and fluoroquinolone combination therapy groups. Primary outcome was 30-day mortality. Propensity score matching (PSM) was used to reduce selection bias.<h4>Results</h4>In total, 631 patients with HAP were enrolled. MonothJournal of Korean medical scienceEmpiric Anti-Pseudomonal β-Lactam Monotherapy Versus Fluoroquinolone Combination Therapy in Patients With Hospital-Acquired Pneumonia: A Multicenter Cohort Study With Propensity Score Matching.PMC105936022019-E2808-00Baek MSKim CLee HBCho WHHong SBPark HKYoo KHJeon KBaek ARChang YKorean HAP/VAP Study GroupShin BMin KHBae SGil HIMoon JYLee HKKim JHOh JYfalseEmpiric Anti-Pseudomonal β-Lactam Monotherapy Versus Fluoroquinolone Combination Therapy in Patients With Hospital-Acquired Pneumonia: A Multicenter Cohort Study With Propensity Score Matching.<h4>Background</h4>There is insufficient data on the benefits of empiric antibiotic combinations for hospital-acquired pneumonia (HAP). We aimed to investigate whether empiric anti-pseudomonal combination therapy with fluoroquinolones decreases mortality in patients with HAP.<h4>Methods</h4>This multicenter, retrospective cohort study included adult patients admitted to 16 tertiary and general hospitals in Korea between January 1 and December 31, 2019. Patients with risk factors for combination therapy were divided into anti-pseudomonal non-carbapenem β-lactam monotherapy and fluoroquinolone combination therapy groups. Primary outcome was 30-day mortality. Propensity score matching (PSM) was used to reduce selection bias.<h4>Results</h4>In total, 631 patients with HAP were enrolled. Monoth2023-01-01T00:00:00Z2023 Oct2026-06-02T19:00:43.429Z2025-04-05T11:48:03.377ZS-EPMC105936023787363310.3346/jkms.2023.38.e353